Browsing Centre for Immunobiology by Subject "value-added medicine"
Now showing items 1-1 of 1
-
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
(2021-02-08)The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to ...